Department of Molecular and Biomedical Science, University of Adelaide, Adelaide, 5005, Australia.
Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, 77030, USA.
Sci Rep. 2021 Mar 23;11(1):6602. doi: 10.1038/s41598-021-86041-4.
Aberrations in the excitatory/inhibitory balance within the brain have been associated with both intellectual disability (ID) and schizophrenia (SZ). The bHLH-PAS transcription factors NPAS3 and NPAS4 have been implicated in controlling the excitatory/inhibitory balance, and targeted disruption of either gene in mice results in a phenotype resembling ID and SZ. However, there are few human variants in NPAS3 and none in NPAS4 that have been associated with schizophrenia or neurodevelopmental disorders. From a clinical exome sequencing database we identified three NPAS3 variants and four NPAS4 variants that could potentially disrupt protein function in individuals with either developmental delay or ID. The transcriptional activity of the variants when partnered with either ARNT or ARNT2 was assessed by reporter gene activity and it was found that variants which truncated the NPAS3/4 protein resulted in a complete loss of transcriptional activity. The ability of loss-of-function variants to heterodimerise with neuronally enriched partner protein ARNT2 was then determined by co-immunoprecipitation experiments. It was determined that the mechanism for the observed loss of function was the inability of the truncated NPAS3/4 protein to heterodimerise with ARNT2. This further establishes NPAS3 and NPAS4 as candidate neurodevelopmental disorder genes.
大脑中兴奋/抑制平衡的异常与智力障碍 (ID) 和精神分裂症 (SZ) 都有关。碱性螺旋-环-螺旋 PAS 转录因子 NPAS3 和 NPAS4 被认为可以控制兴奋/抑制平衡,而在小鼠中靶向破坏这两个基因中的任何一个都会导致类似于 ID 和 SZ 的表型。然而,在 NPAS3 中很少有与精神分裂症或神经发育障碍相关的人类变异体,而在 NPAS4 中则没有。从临床外显子组测序数据库中,我们鉴定了三个 NPAS3 变体和四个 NPAS4 变体,这些变体可能会破坏具有发育迟缓或 ID 的个体的蛋白质功能。通过报告基因活性评估了与 ARNT 或 ARNT2 配对时变体的转录活性,发现截断 NPAS3/4 蛋白的变体导致完全丧失转录活性。然后通过共免疫沉淀实验确定了失活变体与富含神经元的伴侣蛋白 ARNT2 形成异二聚体的能力。结果表明,观察到的功能丧失的机制是截断的 NPAS3/4 蛋白无法与 ARNT2 形成异二聚体。这进一步将 NPAS3 和 NPAS4 确立为候选神经发育障碍基因。